Curanex Pharmaceuticals Inc. announced the closing of its initial public offering of 3,750,000 shares of common stock at a public offering price of $4.00 per share.
The gross proceeds from the offering were $15 million, before deducting underwriting discounts and offering expenses.
The underwriters also have the option to purchase up to 562,500 additional shares of common stock within 45 days from the close of the offering.
Offering Details
3,750,000 shares of common stock were offered at $4.00 per share, resulting in $15 million in gross proceeds.
Underwriters
Dominari Securities LLC led the underwriting with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters.
Legal Counsel
Crone Law Group, P.C. served as counsel to the Company, while Sichenzia Ross Ference Carmel LLP was lead counsel to the underwriters.
SEC Filing
The registration statement on Form S-1 (File No. 333-282686) was declared effective on August 12, 2025.
Future Plans
The Company will advance its lead candidate, Phyto-N, through FDA-required studies and Phase I clinical trials.
- Curanex Pharmaceuticals Inc. aims to develop botanical drugs for inflammatory diseases, focusing on Phyto-N, with proven anti-inflammatory properties.
- Phyto-N has shown positive effects in animal models of various inflammatory diseases, including ulcerative colitis, atopic dermatitis, and COVID-19.
With the successful closing of the initial public offering, Curanex Pharmaceuticals Inc. is poised to advance its lead botanical drug candidate, Phyto-N, in developmental stages for treating inflammatory diseases.